Chemotherapy for Stage II Colon Cancer
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The adjuvant treatment of patients with stage II colon cancer is an area of controversy in medical oncology. Adjuvant chemotherapy aims to eradicate micrometastatic disease present at the time of surgery, preventing the development of distant metastatic disease and thereby curing those patients of their cancer. National and international guidelines for the adjuvant treatment of stage II colon cancer recommend a range of treatment options from observation to chemotherapy with single-agent or combination regimens, depending on the presence or absence of high-risk features (poorly differentiated histology, presence of lymphovascular invasion, presence of perineural invasion, report of < 12 lymph nodes, bowel obstruction, localized perforation, or positive margins). In the one prospective study designed to address the role of adjuvant chemotherapy in stage II colon cancer, a small but statistically significant benefit in overall survival was seen for those patients who received adjuvant chemotherapy; however, multiple meta-analyses and retrospective subgroup analyses have called these findings into question. Though there may be a role for adjuvant chemotherapy in the treatment of patients with stage II colon cancer, its incremental benefit is small, at best, and comes with the risks of real and rarely fatal complications of chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160
Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1825 · Cited by 1,623
Cited by
Győrffy, B. (2024) · The Innovation · doi:10.1016/j.xinn.2024.100625 · Cited by 464
Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges
Koncina, E., Haan, S., Rauh, S., & Letellier, E. (2020) · Cancers · doi:10.3390/cancers12020319 · Cited by 259
MicroRNAs and colorectal cancer chemoresistance: New solution for old problem
Vaghari-Tabari, M., Majidinia, M., Moein, S., Qujeq, D., Asemi, Z., Alemi, F., Mohamadzadeh, R., Targhazeh, N., Safa, A., & Yousefi, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118255 · Cited by 58
A narrative review of genetic factors affecting fluoropyrimidine toxicity
Gmeiner, W. H. (2021) · Precision Cancer Medicine · doi:10.21037/pcm-21-17 · Cited by 25
“However, risks associated with FP-based treatment are real and potentially lethal, and for patients with stage II disease the potential risk-reducing benefits of FP regimens are offset by the potential detrimental effects of treatment (16).”
BackgroundGmeiner, W. H., Dominijanni, A., Haber, A. O., Ghiraldeli, L. P., Caudell, D. L., D’Agostino, R., Pasche, B. C., Smith, T. L., Deng, Z., Kiren, S., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0516 · Cited by 21
“Risk/benefit considerations limit the applicability of 5-FU–based regimens for patients with stage II colon cancer (9), and dose reduction due to toxicity considerations limit 5-FU efficacy for patients with advanced disease.”
Background
Metadata
- Authors
- Varghese, A.
- Venue
- Clinics in Colon and Rectal Surgery
- Publisher
- Georg Thieme Verlag KG
- Published
- 2015-11-22
- Volume
- 28
- Issue
- 04
- Pages
- 256-261
- ISSN
- 1521-5741 (ISSN-L)
- 1531-0043
- 1530-9681
- OpenAlex
- W2270126973
- Cited by
- 82
- References
- 2
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chemotherapy for Stage II Colon Cancer. https://app.cochat.ai/papers/10.1055/s-0035-1564430
- The paper
- Varghese, A. (2015). Chemotherapy for Stage II Colon Cancer. Clinics in Colon and Rectal Surgery. https://doi.org/10.1055/s-0035-1564430
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.